Navigation Links
Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
Date:3/17/2009

INDIANAPOLIS, March 17 /PRNewswire/ -- Semafore Pharmaceuticals, Inc. announced today that it has achieved proof of concept in its CRIMP (Control Resulting from Inhibiting Multiple Pathways) kinase platform by designing a small molecule that was demonstrated to inhibit members of both the PI3K (Phosphoinositide-3-kinase) pathway and the Ras-MAPK (Ras-mitogen activated protein kinase) pathway. Specifically, SF2626 has demonstrated the ability to inhibit both PI3K and MEK, the key component of the RAS/RAF/MEK/ERK pathway. Both PI3K and MEK are frequently activated in human tumors and are thus considered high value targets in treating cancer. SF2626 is the first combination PI3K and MEK kinase inhibitor that, in preclinical studies, blocks both pathways simultaneously.

There is clear rationale for inhibiting both pathways in treating cancer. Both the PI3K pathway and the Ras-MAPK pathways have emerged as central conduits of cell signaling networks that regulate cell growth and survival. Recent scientific studies demonstrate that the Ras-MAPK pathway has the ability to cross-talk to the PI3K pathway thereby activating it and that in some cancers both pathways require inhibition to induce programmed cell death.

Additionally, clinical studies in cancer patients with KRAS mutations show that EGFR inhibitors alone are not sufficient to block the downstream activation of the Ras-MAPK pathway. In these patients, it may also be necessary to block both pathways to inhibit cancer cell growth.

With the evolving knowledge of cancer biology and further understanding of the mechanisms of drug resistance Semafore's CRIMP platform technology offers a distinctive approach to rational drug design for combination pathway kinase inhibitors.

Semafore's dual PI3K-MEK kinase inhibitor, SF2626, is a promising lead for targeting cancer. The Company is actively seeking a partner for the continued development of SF2626 and other pipeline inhibitors.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN. The Company has successfully discovered and is developing a portfolio of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways.

For more information see the company's Web site at www.SemaforePharma.com.


'/>"/>
SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
6. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
7. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device ... consistent, browser-based interface for diagnostic device operations. With this platform, initializing devices and ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional ... passed the U.S. House on May 4, would result in 23 million Americans losing ... implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , “It ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Rob Lowe ... An upcoming production of the series is on hiking in American. Viewers can reconnect ... of the great benefits of hiking. , Many consumers have looked for an inventive ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... be this year’s recipient of proceeds from its 14th Annual Clays for Kids ... E. County Road 30, Bennett, Colorado. , As part of BluSky’s partnership ...
(Date:5/24/2017)... ... 24, 2017 , ... Last month, representatives from Rendina Healthcare ... town officials to celebrate the grand opening of the 87,000 square foot medical ... of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health system. Two ...
Breaking Medicine News(10 mins):